Thelansis

  Adenosine deaminase deficiency (ADA deficiency) is an inherited condition that damages the immune system and is a common cause of severe combined immunodeficiency (SCID). Etiology- Adenosine deaminase deficiency (ADA deficiency) is caused by changes (mutations) in the ADA gene.  This gene is responsible for making an enzyme that is found in specialized white blood cells (lymphocytes). Epidemiology- Adenosine deaminase deficiency (ADA deficiency) affects about 1 in 200,000 – 1 in 1,000,000 people worldwide. About 15% of all cases of severe combined immune deficiency are caused by ADA deficiency. The competitive landscape of Adenosine deaminase deficiency includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary. KOLs insights of Adenosine deaminase deficiency across 8 MM market from the center of Excellence/ Public/ Private hospitals par...